Skip to main content

Usability of the Colli-Pee: a first-void urine self-sampling device (EUROGIN 2018)

Partners: University of Antwerp - Vaccine & Infectious Disease Institute (Belgium), DDL Diagnostic Laboratory (The Netherlands), Institute of Tropical Medicine Department of Clinical Sciences, HIV/STI Reference Laboratory (Belgium), Institute of Tropical Medicine, Department of Public Health, HIV Sexual Unit (Belgium)

Results: Usability of the Colli-Pee^® device was valued ‘very good’ and the design updates of the device were seen as effective.

Usability of the Colli-Pee®: a first-void urine self-sampling device

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.